scholarly journals Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories

Open Biology ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 200247
Author(s):  
Robert E. Hynds ◽  
Kristopher K. Frese ◽  
David R. Pearce ◽  
Eva Grönroos ◽  
Caroline Dive ◽  
...  

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. Although advances are being made towards earlier detection and the development of impactful targeted therapies and immunotherapies, the 5-year survival of patients with advanced disease is still below 20%. Effective cancer research relies on pre-clinical model systems that accurately reflect the evolutionary course of disease progression and mimic patient responses to therapy. Here, we review pre-clinical models, including genetically engineered mouse models and patient-derived materials, such as cell lines, primary cell cultures, explant cultures and xenografts, that are currently being used to interrogate NSCLC evolution from pre-invasive disease through locally invasive cancer to the metastatic colonization of distant organ sites.

2020 ◽  
Vol 21 (22) ◽  
pp. 8782
Author(s):  
Young-Ho Ahn ◽  
Yoon Ho Ko

microRNAs (miRNAs), endogenous suppressors of target mRNAs, are deeply involved in every step of non-small cell lung cancer (NSCLC) development, from tumor initiation to progression and metastasis. They play roles in cell proliferation, apoptosis, angiogenesis, epithelial-to-mesenchymal transition, migration, invasion, and metastatic colonization, as well as immunosuppression. Due to their versatility, numerous attempts have been made to use miRNAs for clinical applications. miRNAs can be used as cancer subtype classifiers, diagnostic markers, drug-response predictors, prognostic markers, and therapeutic targets in NSCLC. Many challenges remain ahead of their actual clinical application; however, when achieved, the use of miRNAs in the clinic is expected to enable great progress in the diagnosis and treatment of patients with NSCLC.


2019 ◽  
Author(s):  
Ellen Voigt ◽  
Hannah Wollenzien ◽  
Josh Feiner ◽  
Ethan Thompson ◽  
Madeline Vande Kamp ◽  
...  

AbstractAlthough many cancer prognoses have improved in the past fifty years due to advancements in treatments, there has been little to no improvement in therapies for small cell lung cancer (SCLC) which currently has a five-year survival rate of less than 7%. One promising avenue to improve treatment for SCLC is to understand its underlying genetic alterations that drive its formation and growth. One such mutation in SCLC, which appears in many cancers, is of the Rb gene. When mutated, Rb causes hyperproliferation and loss of cellular identity. Normally Rb promotes differentiation by regulating lineage specific transcription factors including regulation of pluripotency factors such as Sox2. However, there is evidence that when certain tissues lose Rb, Sox2 becomes upregulated and promotes oncogenesis. To better understand the relationship between Rb and Sox2 and to uncover new treatments for SCLC we have studied the role of Sox2 in Rb loss initiated tumors by investigating both the tumor initiation in SCLC genetically engineered mouse models, as well as tumor maintenance in SCLC cell lines.


2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Christina M. Bebber ◽  
Emily S. Thomas ◽  
Jenny Stroh ◽  
Zhiyi Chen ◽  
Ariadne Androulidaki ◽  
...  

AbstractLoss of TP53 and RB1 in treatment-naïve small cell lung cancer (SCLC) suggests selective pressure to inactivate cell death pathways prior to therapy. Yet, which of these pathways remain available in treatment-naïve SCLC is unknown. Here, through systemic analysis of cell death pathway availability in treatment-naïve SCLC, we identify non-neuroendocrine (NE) SCLC to be vulnerable to ferroptosis through subtype-specific lipidome remodeling. While NE SCLC is ferroptosis resistant, it acquires selective addiction to the TRX anti-oxidant pathway. In experimental settings of non-NE/NE intratumoral heterogeneity, non-NE or NE populations are selectively depleted by ferroptosis or TRX pathway inhibition, respectively. Preventing subtype plasticity observed under single pathway targeting, combined treatment kills established non-NE and NE tumors in xenografts, genetically engineered mouse models of SCLC and patient-derived cells, and identifies a patient subset with drastically improved overall survival. These findings reveal cell death pathway mining as a means to identify rational combination therapies for SCLC.


2008 ◽  
Vol 31 (1) ◽  
pp. 22-28 ◽  
Author(s):  
Boone Goodgame ◽  
Avinash Viswanathan ◽  
C Ryan Miller ◽  
Feng Gao ◽  
Bryan Meyers ◽  
...  

2013 ◽  
Vol 19 (19) ◽  
pp. 5523-5532 ◽  
Author(s):  
Kimberly L. Johung ◽  
Xiaopan Yao ◽  
Fangyong Li ◽  
James B. Yu ◽  
Scott N. Gettinger ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document